4034 - EONS Poster - Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing

Background

Chemotherapy-induced nausea and vomiting (CINV) continue to be a clinical problem, particularly in the delayed phase. Great variability between perception of healthcare professionals and patients, regarding incidence & severity of CINV^1-9. CINV lack of control worsens the quality of life of patients and it is associated with complications^12-13 increasing costs for healthcare services¹⁴.CINV app is a free service addressed to patients treated with emetogenic chemotherapy (CT), empowering patients to report CINV impact in life and relevant information. This study aims to evaluate the usability and acceptability of a smartphone app to improve CINV management in patients receiving CT, by cancer nursing.

Methods

We used 4-dimensions test (content, graphic design, navigation and clinical utility) to evaluate APP's usability and acceptability. Clinical and technical researchers worked together to develop the app’s test. 8 National Hospitals with specialized oncology nursing services were included. 45 cancer nurses invited to participate (from 9 to 23 April 2018) and 33 filled in the test, after making a clinical case simulation through the app.

Results

Described TableTable: CN63

App was easy to use and had relevant content, although improvement is possible. 91% nurses agree that more than 50% of their patients will be able to use the APP and 88% believe that report generated will be useful in practice.

Conclusions

The CINV app addresses main concerns for patients receiving chemotherapy, clinical situation and individual emetic risk of patient or complexity of the prescribed antiemetic regimen and impact of CINV in their daily life. Soliciting feedback from oncology nurses, we ensured that the app was acceptable and beneficial for patients and clinicians. Some points to improve the app in future. Reporting of symptoms after CT enhances CINV management, self-care, and participation without being a burden to patients, indicating that app can be used in clinical practice by patients.

Clinical trial identification

Legal entity responsible for the study

Yolanda Escobar.

Funding

Vifor Pharma.

Editorial Acknowledgement

No conflict of interest

Disclosure

All authors have declared no conflicts of interest.